Barmherzige Brueder gemeinnuetzige Traeger GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Barmherzige Brueder gemeinnuetzige Traeger GmbH in Straubing includes studies in cardiovascular diseases focused on improving care for people with atrial fibrillation, acute coronary syndrome, myocardial infarction, type 2 diabetes, hypertension, and established cardiovascular disease. These trials are designed to evaluate treatment effectiveness and reduce serious heart-related complications.
- Optimizing antiplatelet and anticoagulant treatment in patients with atrial fibrillation and acute coronary events
- Testing a new approach for lowering the risk of cardiovascular death, heart failure hospitalization, or urgent heart care visits
This work reflects a strong focus on better protection against ischemic events, heart failure, and other major cardiovascular outcomes.
Neoplasms
The site is also active in oncology, with trials addressing several neoplasms, including bladder cancer, head and neck squamous cell carcinoma, and chronic lymphocytic leukemia. Research here aims to test new therapies, compare treatment strategies, and improve survival outcomes for patients with difficult-to-treat cancers.
- Evaluating a targeted bladder cancer treatment for tumors with FGFR gene alterations
- Studying sequential therapy approaches for locally advanced head and neck cancer
- Comparing treatment options for previously untreated chronic lymphocytic leukemia
These studies highlight a broad interest in advancing cancer care through more effective and personalized treatment options.
Immune System Processes
Research in immune system processes at this hospital includes trials in psoriasis and psoriatic arthritis, where investigators are examining how well new preventive or supportive approaches are tolerated and how they affect underlying disease activity. The goal is to improve care for chronic inflammatory conditions while maintaining safety.
- Assessing the safety and immune response of vaccination in patients with psoriasis or psoriatic arthritis
This area of study supports better understanding of immune-related disease management and patient well-being.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Janssen Cilag International1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Barmherzige Brueder gemeinnuetzige Traeger GmbH
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Escalated Prasugrel or Ticagrelor with Direct Oral Anticoagulation in Atrial Fibrillation and Acute Coronary Syndrome Undergoing PCI | Klinikum der Universitaet Muenchen AöR | Phase III | Not Recruiting | Dec 2021 | Mar 2026 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 1 | Unknown | 2026-04-29 | 2026-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.